IFITM3 Reduces Retroviral Envelope Abundance and Function and Is Counteracted by glycoGag

Yadvinder S. Ahi,a Diborah Yimer,a Guoli Shi,a Salihya Majdoul,a Kazi Rahman,a Alan Rein,a Alex A. Compton,a

aHIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA

Y.S.A. and D.Y. contributed equally. Y.S.A. (postdoctoral fellow) and D.Y. (predoctoral fellow) contributed equally, but Y.S.A. appears first because he trained and mentored D.Y. and contributed to the conceptualization of the project.

ABSTRACT Interferon-induced transmembrane (IFITM) proteins are encoded by many vertebrate species and exhibit antiviral activities against a wide range of viruses. IFITM3, when present in virus-producing cells, reduces the fusion potential of HIV-1 virions, but the mechanism is poorly understood. To define the breadth and mechanistic basis for the antiviral activity of IFITM3, we took advantage of a murine leukemia virus (MLV)-based pseudotyping system. By carefully controlling amounts of IFITM3 and envelope protein (Env) in virus-producing cells, we found that IFITM3 potently inhibits MLV infectivity when Env levels are limiting. Loss of infectivity was associated with defective proteolytic processing of Env and lysosomal degradation of the Env precursor. Ecotropic and xenotropic variants of MLV Env, as well as HIV-1 Env and vesicular stomatitis virus glycoprotein (VSV-G), are sensitive to IFITM3, whereas Ebola glycoprotein is resistant, suggesting that IFITM3 selectively inactivates certain viral glycoproteins. Furthermore, endogenous IFITM3 in human and murine cells negatively regulates MLV Env abundance. However, we found that the negative impact of IFITM3 on virion infectivity is greater than its impact on decreasing Env incorporation, suggesting that IFITM3 may impair Env function, as well as reduce the amount of Env in virions. Finally, we demonstrate that loss of virion infectivity mediated by IFITM3 is reversed by the expression of glycoGag, a murine retrovirus accessory protein previously shown to antagonize the antiviral activity of SERINC proteins. Overall, we show that IFITM3 impairs virion infectivity by regulating Env quantity and function but that enhanced Env expression and glycoGag confer viral resistance to IFITM3.

IMPORTANCE The viral envelope glycoprotein, known as “Env” in Retroviridae, is found on the virion surface and facilitates virus entry into cells by mediating cell attachment and fusion. Env is a major structural component of retroviruses and is targeted by all arms of the immune response, including adaptive and innate immunity. Less is known about how cell-intrinsic immunity prevents retrovirus replication at the level of individual cells. Here, we show that cellular IFITM3 and IFITM2 inhibit the fusion potential of retroviral virions by inhibiting Env protein via a two-pronged mechanism. IFITM proteins inhibit Env abundance in cells and also impair its function when levels are low. The posttranslational block of retroviral Env function by IFITM proteins is likely to impede both exogenous and endogenous retrovirus replication. In support of a relevant role for IFITM3 in retrovirus control, the retroviral accessory protein glycoGag counteracts IFITM3 function to promote virus infectivity.

KEYWORDS IFITM, fusion, innate immunity, retroviruses, Env, viral glycoprotein

Mammals encode, as part of their innate immune systems, a number of proteins that interfere with viral infections in a cell-autonomous manner. Several of these are induced by interferon, which promotes an “antiviral state” in cells. In recent years,
a number of host proteins have been identified that interfere with the synthesis, trafficking, and/or function of HIV-1 Envelope (Env), the viral glycoprotein that mediates virus attachment and fusion (1, 2). Among them are MARCH8, guanylate-binding proteins (GBP), ERManI, p90K, serine incorporator (SERINC) proteins, and the interferon-induced transmembrane (IFITM) proteins (3–10). The IFITM proteins, IFITM3 in particular, are known for inhibiting the entry of a wide array of viruses into host cells (11), and they also interfere with the fusogenicity of HIV-1 virions when expressed in virus-producing cells (12, 13). In both cases, the mechanisms of action are poorly understood.

While the precise mechanisms by which IFITM proteins decrease the fusogenicity of virions remain unclear, it is clear that Env is the major determinant governing sensitivity to inhibition by IFITM3. For example, certain strains of HIV-1 exhibit resistance to the IFITM3-mediated loss of virion infectivity, and resistance maps to the V3 region of Env (14). Moreover, endogenous IFITM3 colocalizes with HIV-1 Env in infected, primary CD4+ T cells (12). Ectopic IFITM3 has been reported to coimmunoprecipitate with HIV-1 Env in virus-producing 293T cells and to inhibit the proteolytic processing of the Env precursor, gp160, resulting in decreased virion incorporation of the gp120 (surface [SU]) and gp41 (transmembrane [TM]) units (15). However, the processing defect of Env may be cell type dependent because it was apparent in some cells (293T) but not in others (T lymphocytes) (7, 16, 17). Thus, a complete understanding of how IFITM3 impacts Env function is lacking.

The inhibition of virus infectivity by IFITM3 is not restricted to lentiviruses. The infectivities of HIV-based virus-like particles pseudotyped with murine leukemia virus (MLV) Env, vesicular stomatitis virus glycoprotein (VSV-G), and influenza A virus hemagglutinin are impaired by the presence of IFITM3 in virus-producing cells (13, 18). Furthermore, full-length, replication-competent viruses, including MLV, dengue virus, and Ebola virus (EBOV) are also subject to inhibition of virion infectivity by IFITM3 (19). The breadth exhibited by IFITM3 in its capacity to inhibit virion infectivity suggests that it does so via a general mechanism and not through specific binding of viral glycoproteins.

In the present work, we investigated the effects of IFITM proteins on MLV pseudotypes carrying MLV Env or other viral glycoproteins. We report that the presence of IFITM3 and IFITM2 in virus-producing cells reduces viral infectivity. This reduction is due in part to the redirection of Env precursors to endolysosomes, leading to their degradation, and in part to impairment of the fusogenicity of the Env protein incorporated into virus particles. Surprisingly, these IFITM effects were counteracted by the MLV accessory protein glycoGag. The results provide significant new information on mechanisms of IFITM function.

RESULTS
IFITM3 reduces MLV infectivity by inhibiting Env in virus-producing cells. To address the impact of IFITM3 on MLV virion infectivity and to identify the mechanisms involved, we produced MLV-based virus-like particles (here referred to as virus) in 293T cells via cotransfection of an MLV Gag-Pol plasmid, an MLV Env plasmid, an expression plasmid for human IFITM3, and an MLV-based luciferase plasmid. Released virions were assessed for infectivity on permissive target cells and characterized by immunoblotting. As shown in Fig. 1A and B, IFITM3 reduced virus-specific infectivity in a dose-dependent manner, with similar effects on viruses carrying ecotropic or xenotropic Env (Fig. 1A and B). Similar restriction was seen for full-length Moloney MLV, in which ecotropic Env was encoded in cis rather than on a separate plasmid (see Fig. S1A in the supplemental material).

As one approach to identifying the step(s) in the infection process that is sensitive to inhibition by IFITM3, we tested the ability of viruses to enter new host cells using an assay that quantifies the delivery of Cre recombinase packaged into virions (20). The results showed that the loss in infectivity in virions produced in IFITM3-containing cells was closely correlated with their ability to enter cells; this has been previously shown with HIV-1 (12, 13) (Fig. S1B).
FIG 1 IFITM2 and IFITM3 inhibit MLV infectivity and decrease Env levels in virus-producing cells. (A) 293T were cotransfected with env-deficient MLV (2.5 μg), pBabeLuc (0.6 μg), ecotropic Env (0.5 μg), and empty pCMV6 or pCMV6-IFITM3 (0.03, 0.09, 0.27, or 0.81 μg). (B) Same as in panel A, except that xenotropic Env was used. (C) 293T were cotransfected with env-deficient MLV (2.5 μg), pBabeLuc (0.6 μg), ecotropic Env (0.5 or 0.1 μg), and empty pCMV6 or pCMV6-IFITM3 (0.27 μg). (D) Same as in panel C, except that (Continued on next page)
Like all retroviral Env proteins, MLV Env is cleaved by a furin-like cellular protease into the SU and the TM units as it is trafficked to the cell surface. However, the MLV TM is cleaved again near its C terminus during maturation of the released virus. This truncation of TM appears to activate the membrane-fusing potential of the Env complex; one manifestation of this potential is the ability of the truncated Env to induce fusion between cells expressing this protein and cells expressing the surface receptor for the virus (21, 22). We also found that IFITM3 inhibited cell-cell fusion mediated by this truncated (‘R-’) Env (Fig. 1C). Taken together, the results in Fig. 1B and C suggest that IFITM3 blocks retroviral infectivity by interfering with the ability of viral Env to induce membrane fusion, as required for successful infection of new target cells.

In the initial experiments presented in Fig. 1A and B, we produced MLV in the presence of various amounts of IFITM3 expression plasmid. To further explore the relationship between IFITM3 and virus entry, we produced MLV with or without IFITM3 in the presence of various levels of Env. Interestingly, we found that reducing the amount of Env dramatically increased the sensitivity of virus to inhibition by IFITM3 (Fig. 1C and D). These results indicate that the effect of IFITM3 on retroviral infectivity is most potent when Env levels are limiting. Immunoblotting of these samples showed that inhibition of MLV infectivity by IFITM3 was associated with a reduction in Env proteins in cells and in virions produced by these cells (Fig. 1C and D). These results demonstrate that one effect of IFITM3 expression is to decrease the level of Env protein in cells.

However, quantitative comparisons showed that the reduction in virion-associated Env does not fully explain the loss of infectivity imparted by IFITM3. For example, virus produced with 0.5 μg of ecotropic Env plasmid (‘HI ENV’) in the presence of IFITM3 (red bar, second lane) contains significantly more Env protein than virus produced with 0.1 μg of Env plasmid (‘LO ENV’) in the absence of IFITM3 (blue bar, third lane), and yet the former is no more infectious than the latter (Fig. 1C). Similarly, virus produced with 0.5 μg of xenotropic Env plasmid (‘HI ENV’) in the presence of IFITM3 (red bar, second lane) contains more Env protein than virus produced with 0.1 μg of Env plasmid (‘LO ENV’) in the absence of IFITM3 (blue bar, third lane), and yet the former is less infectious than the latter (Fig. 1D). Thus, the inhibition of virion infectivity by IFITM3 does not result solely from a decrease in virus-associated Env. It appears that IFITM3 exerts two inhibitory effects: a reduction of Env protein available for incorporation into assembling virions and a reduction of the fusogenic capacity of virions made with the Env that remains.

Further examination of the immunoblots also revealed that IFITM3 expression resulted in an apparent Env processing defect, such that the amount of Env precursor gp85, relative to that of its cleavage product gp70 (SU), was greater in IFITM3-containing cells than in the control cells (Fig. 1C and D). Quantification of multiple immunoblots indicated that IFITM3 lowers the gp70/gp85 ratio of both ecotropic and xenotropic Env (Fig. 1D).

IFITM3 is a known resident of extracellular vesicles (23, 24) but is also a bona fide virion-associated protein (12, 13, 19, 25). IFITM3 was readily detectable in virus-containing supernatants (Fig. 1C and D), and IFITM3 levels were far higher in pellets from supernatants which contained virus than in those that did not (Fig. 1E). None-
theless, in contrast to Env, the quantity of IFITM3 in supernatants did not clearly correlate with loss of virion infectivity (Fig. 1C and D).

Since the first antiviral function ascribed to the IFITM proteins was that of protecting naive target cells from virus infections, we challenged cells stably expressing IFITM3 with MLV pseudotyped with xenotropic Env. While IFITM3 in virus-producing cells strongly inhibited infection, IFITM3 in target cells did not significantly inhibit infection (Fig. S1F). We also tested whether the ability to inhibit MLV infectivity was shared among related IFITM proteins. Human IFITM2, but not IFITM1, restricted MLV infectivity to a similar degree as human IFITM3, and murine Ifitm3 also performed this function albeit to a slightly lesser extent (Fig. 1E and F). Restriction by each IFITM homolog was associated with a loss of Env from virions, consistent with the idea that quantitative regulation of Env is a contributor to the restriction phenotype.

We also performed analogous experiments on particles with HIV-1 cores and HIV-1 Env. Just as with MLV, restriction of HIV-1 infectivity by IFITM3 was maximal when small amounts of HIV-1 Env were used to pseudotype particles (Fig. 2). Furthermore, levels of gp120 (SU) and gp41 (TM) in supernatants were modestly diminished in the presence of IFITM3 (Fig. 2).
IFITM3 inhibits infectivity driven by VSV-G but not EBOV GP. It was also of interest to assess the breadth of the antiviral activity of IFITM3. We therefore tested MLV particles carrying nonretroviral glycoproteins VSV-G and EBOV glycoprotein (EBOV GP). In our initial experiments, we saw no reduction in the infectivity of these particles by IFITM3 (Fig. 3A and B). However, when we reduced the amounts of VSV-G and EBOV GP plasmids in the transfections, we found that the VSV-G pseudotype was rendered sensitive to IFITM3 (Fig. 3C). As observed with MLV Env, inhibition of VSV-G-mediated infectivity at low doses of VSV-G was accompanied by a reduction in the level of VSV-G incorporation (Fig. 3C). In contrast, IFITM3 showed no ability to inactivate EBOV GP, even when transfection of less EBOV GP plasmid resulted in decreased infectivity (Fig. 3D). It should be noted that a prior report indicated that intact, replication-
IFITM3 Inhibits Retroviral Envelope Function

competent EBOV was impaired in infectivity by IFITM3 (19); our disparate observations could be reconciled if EBOV proteins other than GP contribute to sensitivity to IFITM3.

**IFITM3 interferes with Env trafficking and promotes its degradation in endolysosomes.** The data presented above show that expression of IFITM3 together with viral Gag, Pol, and Env proteins leads to a reduction in the level of Env in cells (and in virions). To simplify our analysis, we also tested the effect of IFITM3 on Env levels in the absence of other viral constituents. As shown in Fig. 4A, the IFITM3 expression plasmid drastically reduced the level of ecotropic Env protein in cells in cotransfected cells. Interestingly, the levels of two cellular glycoproteins, EGFR and IGF-1R, were unaffected (Fig. 4A). These results suggest that IFITM3 selectively reduces the quantity of viral glycoproteins without generally impacting cellular glycoproteins.

Two major routes of intracellular protein degradation are the endolysosomal and proteasomal pathways. To determine whether one of these was involved in the loss of
viral glycoprotein from cells expressing IFITM3, we tested the effect of bafilomycin A1 (BafA1), which inhibits endolysosomal acidification, and of MG132, a proteasome inhibitor. As shown in Fig. 4B, BafA1 rescues Env protein from IFITM3-induced loss, while MG132 had no effect (Fig. S2A). However, the Env protein detected in the presence of BafA1 also migrated more slowly in SDS-PAGE than the gp70 (SU) in control cells. In fact, it exhibited the same mobility as the gp85 precursor, as shown by comparison to an Env mutant defective for furin-mediated processing (R469A) (Fig. 4B). Taken together, these results suggest that IFITM3 interferes with furin-catalyzed processing of the Env precursor, followed by its degradation in endolysosomes.

It was also of interest to visualize the effects of IFITM3 on Env protein localization in living cells. For this purpose, we used an MLV Env protein that contains EGFP, but retains full functionality (26). We localized endolysosomes both with LAMP1-RFP and with LysoTracker. As shown in Fig. 4C, the Env protein exhibited extensive plasma membrane localization and was also present in perinuclear regions. In contrast, in the presence of IFITM3, the Env signal was absent from the plasma membrane and instead accumulated in LAMP1-positive endolysosomes. Similar colocalization between Env and LysoTracker is shown in Fig. S2B. It is interesting to note that the antiviral function of IFITM3 in target cells involves the apparent degradation of incoming virions in endolysosomes as well (27, 28). We calculated Mander’s coefficients to quantify the proportion of Env-GFP colocalizing with LAMP1-RFP in the absence (0.20 ± 0.06) or presence (0.48 ± 0.03) of IFITM3. We also visualized a fluorescently tagged version of IFITM3 (IFITM3-mCherry) and Env-EGFP and found that the two signals partially colocalized in vesicular structures that are likely endolysosomes (Video S1).

Together, our findings demonstrate that ectopic IFITM3 interferes with MLV Env processing and trafficking and leads to Env degradation in endolysosomes, resulting in a paucity of Env incorporation into virions.

Endogenous IFITM3 negatively regulates Env protein accumulation. While the data presented so far illustrate the impacts of ectopic IFITM3 on MLV Env, it was unknown whether endogenous IFITM3 in human or murine cells restricts Env accumulation. When we transfected equal amounts of ecotropic Env plasmid into HeLa and HeLa IFITM3 knockout (KO) cells, we found that more Env protein was present in the KO cells (Fig. 5A). When human IFITM3 was reintroduced into IFITM3 KO cells, Env detection was suppressed. Similar results were obtained with xenotropic Env (Fig. S3A). We also tested the possibility that transfection was more efficient in the KO cells than in the control cells by transfecting a Gaussia luciferase expression vector; as shown in Fig. S3B, Gaussia luciferase production was not markedly affected by IFITM3 KO.

In an additional test of the idea that endogenous IFITM3 reduces Env protein levels, we used RNAi-mediated knockdown of IFITM3 to suppress IFITM3 expression. As shown in Fig. 5B, Env plasmid transfection into cells treated with IFITM3 small interfering RNA (siRNA) led to an increase in intracellular Env levels relative to cells treated with control siRNA.

We also took advantage of the availability of mouse embryonic fibroblasts (MEFs) from mice in which the Ifitm locus had been ablated (IfitmDel mice) to visualize the effects of murine ifitm proteins on viral Env quantity and localization. We confirmed by immunoblotting that murine Ifitm3 is undetectable in IfitmDel cells (Fig. S3C). The Env-EGFP plasmid was transfected into MEF wild type (WT) and MEF IfitmDel and, as shown in Fig. 5C, the Env-EGFP signal exhibited greater intensity and a greater extent of apparent cell surface localization in MEF IfitmDel cells than in MEF WT cells, as determined by both confocal microscopy and flow cytometric analysis (Fig. 5C and see Fig. S3D in the supplemental material). Introduction of murine Ifitm3 into IfitmDel cells reduced overall Env-EGFP detection, and treatment with BafA1 led to the partial recovery of intracellular Env-EGFP signal (Fig. 5C). In contrast, expression of a construct encoding EGFP alone was comparable between the MEF WT and MEF IfitmDel (Fig. S3D). These results suggest that endogenous human and murine IFITM3/Ifitm3 are both negative regulators of MLV Env proteins.
GlycoGag rescues retroviral infectivity in the presence of IFITM3. In inhibiting HIV-1 infectivity when expressed in virus-producing cells, the IFITM proteins resemble members of another family of transmembrane proteins known as SERINC (4, 5). Moreover, it was found that Nef of HIV-1, S2 of EIAV, and glycosylated Gag (glycoGag) of MLV all antagonize the antiviral function of SERINC3 and SERINC5 (4, 5, 20, 29). Importantly, a glycoGag-negative MLV clone was used in our experiments described above. To examine the effects of glycoGag on IFITM3 activity, we compared the antiviral restriction activities of IFITM3 and SERINC5 against MLV pseudotyped with xenotropic and ecotropic Env. In these experiments, MLV clones were used in which the glycoGag coding region had either been destroyed or remained intact (20). Ectopic expression of IFITM3 and SERINC5 restricted infectivity driven by xenotropic Env by 20- and 50-fold, respectively (Fig. 6A). We were unable to detect ectopic SERINC5 produced under these conditions by Western blotting (Fig. S4A). Unlike IFITM3, SERINC5 did not affect Env levels (Fig. 6A). As previously described (20), in cis expression of glycoGag partially rescued the virus infectivity defect imposed by SERINC5. Unexpectedly, the loss of infectivity imparted by IFITM3 was also partially rescued by glycoGag (Fig. 6A). In contrast, the infectivity of virus produced with ecotropic Env or VSV-G was restricted by IFITM3, but glycoGag did not augment infectivity in either case (Fig. S4B and C). These results suggest that the influence of glycoGag on virion infectivity is viral glycoprotein dependent.

We also tested whether glycoGag supplied in trans was capable of overcoming restriction by IFITM3. We previously found that a limited quantity of glycoGag protein is needed to rescue MLV infectivity in the presence of SERINC5 and that larger amounts of glycoGag are detrimental to virion infectivity (20). Here, small quantities of glycoGag,
FIG 6 glycoGag rescues retroviral infectivity in the presence of IFITM3. (A) 293T were cotransfected with env-deficient MLV encoding or not encoding glycoGag (2.5 μg), pBabeLuc (0.6 μg), xenotropic Env (0.5 μg), and empty pCMV6, pCMV6-IFITM3 (0.83 μg), or pBJ5-SERINC5 (0.093 μg). (B) 293T were cotransfected with env-deficient MLV (2.5 μg), pBabeLuc (0.6 μg), xenotropic Env (0.5 μg), and empty pCMV6, pCMV6-IFITM3 (0.27 μg). Under the indicated conditions, pCMV-glycoGag-myc of pCMV-glycoGag Y36A-
which were undetectable by Western blotting (Fig. S4D), largely restored infectivity in the presence of IFITM3 (Fig. 6B). In contrast, glycoGag mutated in its AP-2 recognition motif (Y36A) did not, suggesting that endocytosis of glycoGag is necessary for its ability to counteract the effects of IFITM3 (Fig. 6B). Intriguingly, immunoblotting revealed that glycoGag did not alter the levels of Env or IFITM3 (Fig. 6C). These data represent the first demonstration of a viral accessory protein conferring resistance to an IFITM protein. Moreover, the fact that glycoGag expression confers resistance to IFITM3 without affecting Env quantity suggests that glycoGag blocks a cryptic function of IFITM3 which impairs the fusogenic potential of virions.

**DISCUSSION**

Much of our understanding of the interplay between retroviruses and host immunity derives from the study of primate lentiviruses, namely, HIV-1 and its ancestor, SIV (30–33). In addition, the coevolution of MLV and mice over millions of years has been used to reveal mechanisms of host control of exogenous and endogenous viral forms (34, 35). Here, we used MLV to dissect the antiviral mechanism of IFITM3 and to discover modes of viral evasion.

We found that IFITM3 inhibits the proteolytic processing of the MLV Env precursor, resulting in decreased glycoprotein incorporation into virions. In addition, IFITM3 directs Env toward lysosomes for proteolytic degradation, which is likely a feature of how IFITM3 inhibits HIV-1 Env and VSV-G as well. Therefore, we have shown that IFITM3 negatively regulates several retroviral and nonretroviral glycoproteins, revealing that this function is not specific to HIV-1 Env and thus unlikely to result from a specific IFITM3-Env interaction. Rather, IFITM3 may reroute viral glycoprotein traffic in a non-specific manner via its ability to impact vesicular trafficking and fusion events. We believe that IFITM3 shunts Env away from the secretory pathway at a stage prior to the trans-Golgi network (TGN), where cleavage by a furin-like protease occurs. Blotting of Env mutated in the furin recognition site (R469A) revealed a slow-migrating molecular species that is likely Env modified with complex carbohydrates, a transient decoration that is applied during passage through the Golgi compartment. However, no such bands were detected on Env expressed in the presence of IFITM3, suggesting that IFITM3 results in Env trafficking away from the Golgi compartment where complex carbohydrates are added (Fig. 4B). Therefore, our results may suggest that IFITM3 reroutes Env from the endoplasmic reticulum or from an early Golgi compartment toward endolysosomes, preventing an encounter with furin in the TGN and thus giving rise to the observed processing defect.

Our data also show that inhibition of virus infectivity by IFITM3 does not solely result from reductions in Env quantity. By experimentally limiting viral glycoprotein incorporation into virions, we show that the impact of IFITM3 on virion infectivity is greater than the impact of reducing viral glycoprotein incorporation. These data suggest that Env function itself may be targeted by IFITM3, and certain possibilities include the inhibition of Env trimer formation, the inhibition of trimer mobility or trimer clustering in virions, or the inhibition of membrane fusion activity. The quantitative and qualitative impacts of IFITM3 on Env may represent a two-pronged approach that allows IFITM3 to more potently inhibit virion infectivity, since the reduction of Env protein levels sensitizes virus to the effect of IFITM3 on Env function.

We also found that viruses incorporating greater amounts of Env are less sensitive to restriction by IFITM3 in virus-producing cells. Intriguingly, IFITM proteins can also

---

**FIG 6 Legend (Continued)**

myc (0.01 or 0.03 μg) were included. The specific infectivities of viruses produced by transfected cells were measured as described in Materials and Methods. (C) Transfected cells were lysed at 72 h posttransfection, and virus-containing supernatants from 48 and 72 h posttransfection were filtered, ultracentrifuged through 20% sucrose. Then, SDS-PAGE and Western blotting were performed. The data represent the averages of three independent experiments; for each experiment, infectivities were measured in triplicate and averaged. Statistical analysis in panel A was performed with the Student t test. Statistical analysis in panel B was performed using one-way ANOVA. *P < 0.05; **P < 0.0005.
restrict lentiviral infections when they are present in target cells, rather than virus-producing cells, and the extent of lentiviral Env incorporation into virions is also a determinant of this restriction (36). The link between virion-associated Env and sensitivity to IFITM proteins is further supported by a recent publication. Sharma et al. discovered that the use of Env variants which are adapted to macaque lymphocytes confers chimeric SIV-HIV (SHIV) with resistance to macaque IFITM proteins. Importantly, SHIV encoding macaque-adapted Env were distinguished by two features: (i) they incorporated much higher levels of Env, and (ii) they incorporated much less IFITM3 compared to their nonadapted counterparts (25).

Overall, these results suggest that IFITM3 regulates both the abundance of Env and its function in virions, revealing an additional layer of innate protection likely to be important for the suppression of exogenous and endogenous retroviruses in multiple species. Our demonstration that endogenous Ifitm proteins in murine cells inhibit the accumulation of MLV Env suggest that they may be constituents of the cell-intrinsic machinery that suppresses endogenous retroviruses (37). Indeed, it was recently reported that IFITM proteins inhibit the activity of Syncytin proteins, which are encoded by endogenous retroviral env genes and have been coopted by host cells to mediate placental trophoblast fusion (38, 39).

Of all the cellular antiviral proteins targeting Env function, SERINC3/5 may be of particular importance because it is counteracted by retroviral accessory proteins Nef (HIV-1), glycoGag (MLV), and S2 (EIAV). Here, we present evidence that IFITM3 function is also overcome by glycoGag. This represents the first description of a viral auxiliary protein capable of overcoming IFITM3 and restoring virion infectivity. Our data suggest that glycoGag does not alter levels of IFITM3 or Env, hinting that it counteracts the effect of IFITM3 on Env function. Since glycoGag was previously shown to antagonize SERINC5, our data raise the intriguing possibility that IFITM3 function is linked to that of SERINC5. It has been reported that glycoGag and Nef reduce SERINC5 expression by directing it to endolysosomes for degradation (40, 41). Furthermore, glycoGag requires an AP-2-binding site to overcome the effects of both SERINC5 (42) and IFITM3, indicating that internalization of glycoGag is important for its function. Important future work will probe the functional interdependence between IFITM proteins and SERINC family members in virus restriction.

MATERIALS AND METHODS

Cell lines and plasmids. All cell lines were cultured in Dulbecco modified Eagle medium containing 10% fetal calf serum and 1% penicillin-streptomycin (Thermo Fisher). 293T and HeLa cells were obtained from ATCC (CRL-3216 and CCL-2, respectively). IFITM3 KO HeLa cells were generated by CRISPR/Cas9 and described previously (43). 293T/mCAT1 cells were generated with pcDNA-mCAT1 (a gift from Lorraine Albritton) (44). HT1080/mCAT1 cells were described previously (20). MEFs and IfitmDel MEFs were kindly provided by Michael S. Diamond (Washington University) (45, 46). pCMV6-XL5 encoding untagged human IFITM1, IFITM2, or IFITM3 was purchased from Origene (SC117830, SC124192, and SC112616). pQCXIP encoding FLAG-Ifitm3 was obtained from Chen Liang (McGill University). The following plasmids used in this study have been described previously: plasmids encoding env-deficient Moloney MLV Gag-Pol with or without glycoGag (20), pCMV-glycoGag-myc and pCMV-glycoGag Y36A-myc (20), a plasmid encoding HIV-1 NL4.3 lacking vpr and containing luciferase in place of env (a gift from Vineet KewalRamani and Alok Mulky), pBabeLuc (47), pCD-Env encoding ecotropic Env (48), pCMV-Xenogp85 expressing xenotropic Env (a gift from Heinrich G. Gottlinger [University of Massachusetts]), p8L-NL encoding HIV-1 NL4.3 Env (a gift from Eric O. Freed), pCMV-VSV-G encoding the vesicular stomatitis virus G protein (Addgene, catalog no. 8454), pCAGGS-EboGPz encoding Ebolavirus Zaire glycoprotein (a gift from Paul Bates [University of Pennsylvania]) (49), pBJS-SERINC5 (5), and a plasmid encoding MLV Gag-Cre fusion protein (20). pCD-Env-EGFP encoding GFP-tagged ecotropic Env was created by inserting EGFP into pCD-Env between residues 265 and 273 as outlined previously (26). The plasmids used for the Double Split Protein-based cell fusion assay (pDSP 1-7 and pDSP 8-11) were a gift from Zene Matsuda (University of Tokoyo) (50). IFITM3-mCherry (amino-terminal tag) was produced by Genecopoeia. A plasmid encoding Gaussia luciferase was a gift from Stanislas Kaczmarczyk, and pcDNA-EGFP was obtained from Addgene (catalog no. 13031).

Virus production and infectivity assay. Virus was produced in 293T via transient transfection with Mumps TransitT-293. Briefly, 400,000 293T cells were seeded in a 6-cm dish. For MLV-based pseudotype production, cells were cotransfected with a plasmid encoding env-deficient MLV Gag-Pol with or without glycoGag (2.5 μg), a glycoprotein expression plasmid (various amounts), pBabeLuc (0.6 μg), and pUC-CMV as a filler plasmid to bring the total DNA amount to 5 μg per transfection. Depending on the experiment, transfections also included various amounts of pCMV6-IFITM1, pCMV6-IFITM2, pCMV6-
IFITM3, pQCXIP-Ifitm3 (murine), or pBS5-SERINC5. For HIV-1-based pseudotype production, cells were cotransfected with pNL4.3 Luc (2.5 μg), pIII-NL-Env (variable amounts), and pUC-CMV as a filler plasmid to bring total DNA amount to 5 μg per transfection. Virus-containing supernatants were harvested at 48 and 72 h posttransfection, combined, and filtered through 0.45-μm-pore size filters. For infectivity measurements, HT1080/mCAT1 cells (for MLV pseudotypes) and TZM.bl (HIV-1 pseudotypes) were used as target cells and seeded in 6-well plates at 100,000 cells per well. The following day, cells were infected with 0.5 ml of the virus-containing supernatant and firefly luciferase activity was measured in cell lysates at approximately 48 h postinfection. Luciferase assays were performed using luciferase assay system (Promega) according to the manufacturer's protocol. Firefly luciferase assay output was normalized to the amount of input virus as determined by quantitative anti-CA immunoblotting of the filtered, virus-containing supernatant following ultracentrifugation through 20% sucrose. The normalized luciferase assay output was designated as “specific infectivity.”

**Western blot analysis.** Virus was produced in 293T via transient transfection of Moloney MLV without glycoGag (2.5 μg), a plasmid encoding Gag-Cre (0.5 μg), and empty pCMV6 or pCMV6-IFITM3 (0.27 or 0.81 μg). Virus-containing supernatants were harvested at 48 and 72 h posttransfection, combined, filtered through 0.45-μm-pore size filters, and used to infect HT1080/mCAT1 cells stably expressing a Cre-dependent luciferase cassette known as p231 (20). Virus entry into cells was determined by luciferase assay of infected cells at 48 h after virus addition. Firefly luciferase assay output was normalized to the amount of input virus as determined by quantitative anti-CA immunoblotting of the filtered, virus-containing supernatant following ultracentrifugation through 20% sucrose. The normalized luciferase assay output was designated as “specific entry.”

**Enzyme-linked immunosorbent assay (ELISA).** Cells were treated with 1 or 5 μg/ml of gp120b (NIH AIDS Reagent Resource, catalog no. 288), human anti-gp41 (Proteintech, catalog no. 1475), mouse anti-p24 CA (NIH AIDS Reagent Resource, catalog no. 3537), rabbit anti-Ifitm3 (Abcam, ab109429 [EP2S242]), mouse anti-IFITM2/3 (Proteintech, 66081-1-lg), mouse anti-IFITM-1 (Proteintech, 60074-1-lg), rabbit anti-Fragilis (Abcam, ab15592, for detection of murine ifitm3), rabbit anti-SERINC5 (Abcam, ab204400), mouse anti-FLAG M2 (Sigma, F1804), mouse anti-myc 9E10 (Sigma, M4439), rabbit anti-VSV-G (BioLegend, 903901), mouse anti-Ebola GP (clone 6D8, a gift from Rajini Mudhasini, USAIMRID), mouse anti-IGFR-1b (Santa Cruz Biotechnology, sc-390130), mouse anti-EGFR (Abcam, ab32077), and mouse anti-actin (Santa Cruz Biotechnology, C4 sc-47778). Secondary antibodies conjugated to DyLight 800 or 680 (Li-Cor) were used to reveal specific protein detection. Images were analyzed and assembled using ImageStudioLite (Li-Cor).
assay buffer (Thermo Fisher) containing HALT protease inhibitor (Thermo Fisher) and sonicated. Lysates were mixed with equal volume of 1× NuPAGE LDS sample buffer with 1× NuPAGE sample reducing agent and processed for Western blot analysis as described above.

**Cell-cell fusion assay.** Cell-cell fusion assays were performed using the double split protein system, as previously described (50), with some modifications. 293T cells were seeded in six-well plates at 300,000 cells per well and transfected with Mirus TransIT-LT1. Stably expressing cells were created following selection with puromycin for more than 2 weeks. Cells were challenged with MLV pseudotyped with empty pQCXIP (Empty) or pQCXIP-FLAG-IFITM3 were transfected into 293T cells with Mirus TransIT-LT1. Stably expressing cells were created following selection with puromycin for more than 2 weeks. Cells were challenged with MLV pseudotyped with xenotropic Env produced in the presence or absence of IFITM3 and infection was quantified by measuring firefly luciferase activity at approximately 48 h postinfection (as described above).

**Virus challenge of IFITM3-positive cells.** Empty pQCXIP (Empty) or pQCXIP-FLAG-IFITM3 were transfected into 293T cells with Mirus TransIT-LT1. Stably expressing cells were created following selection with puromycin for more than 2 weeks. Cells were challenged with MLV pseudotyped with xenotropic Env produced in the presence or absence of IFITM3 and infection was quantified by measuring firefly luciferase activity at approximately 48 h postinfection (as described above).

**Statistical analysis.** The Student t test or a one-way analysis of variance (ANOVA) was used for determination of statistically significant differences. The specific test used is indicated in each figure legend. In most cases, only comparisons yielding a statistically significant difference are called out in the figure (*, P < 0.05; **, P < 0.0005).

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**VIDEO S1**, AVI file, 2.8 MB.

**FIG S1**, PDF file, 1.6 MB.

**FIG S2**, PDF file, 2.7 MB.

**FIG S3**, PDF file, 1 MB.

**FIG S4**, PDF file, 0.2 MB.

**ACKNOWLEDGMENTS**

We thank the Optical Microscopy and Image Analysis Lab at the National Cancer Institute for their assistance in image acquisition, Demetria Harvin and Peter Lai for technical assistance, and Eric O. Freed for providing critical feedback.

**REFERENCES**

1. Beitari S, Wang Y, Liu S-L, Liang C. 2019. HIV-1 Envelope glycoprotein at the interface of host restriction and virus evasion. Viruses 11:311–316. https://doi.org/10.3390/v11040311.

2. Compton AA, Schwartz O. 2017. They might be giants: does syncytium formation sink or spread HIV infection? PLoS Pathog 13:e1006099. https://doi.org/10.1371/journal.ppat.1006099.

3. Braun E, Hotter D, Koepeke L, Zech F, Gross R, Sparrer KMJ, Müller JA, Fackler OT, Kirchhoff F, Sauter D. 2019. Guanylate-binding proteins 2 and 5 exert broad antiviral activity by inhibiting furin-mediated processing of viral Envelope proteins. Cell Rep 27:2092–2104.e2010. https://doi.org/10.1016/j.celrep.2019.04.063.

4. Compton AA, Bruel T, Porrot F, Mallet A, Sachse M, Euvrard M, Liang C, Casartelli N, Schwartz O. 2014. IFITMs restrict the replication of multiple pathogenic viruses. J Mol Biol 425:4937–4955. https://doi.org/10.1016/j.jmb.2014.11.001.

5. Compton AA, Bruel T, Porrot F, Mallet A, Sachse M, Euvrard M, Liang C, Casartelli N, Schwartz O. 2014. IFITMs restrict the replication of multiple pathogenic viruses. J Mol Biol 425:4937–4955. https://doi.org/10.1016/j.jmb.2014.11.001.

6. Guàrdia J, Pérez-Sierra D, Carmona-Pacheco S, Fujita H, Tokunaga K. 2015. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins. Nat Med 21:1502–1507. https://doi.org/10.1038/nm.3956.

7. Wei W, Yu XF. 2016. HIV-1 Envelope under attack. Trends Microbiol 24:164–166. https://doi.org/10.1016/j.tim.2016.01.004.

8. Perreira JM, Chin CR, Feeley EM, Brass AL. 2013. IFITMs restrict the replication of multiple pathogenic viruses. J Mol Biol 425:4937–4955. https://doi.org/10.1016/j.jmb.2013.09.024.

9. Wang Y, Pan Q, Ding S, Wang Z, Yu J, Finzi A, Liu S-L, Liang C. 2017. The V3 loop of HIV-1 Env determines viral susceptibility to IFITM3 impairment of viral infectivity. J Virol 91:e02441-16. https://doi.org/10.1128/JVI .02441-16.

10. Ju Y, Li M, Wilkins J, Ding S, Swartz TH, Esposito AM, Zheng Y-M, Freed EO, Liang C, Chen BK, Liu S-L. 2015. IFITM proteins restrict HIV-1 infection by antagonizing the Envelope glycoprotein. Cell Rep 13:145–113. https://doi.org/10.1016/j.celrep.2015.08.055.

11. Jakobsdottir GM, Iliopoulou M, Nolan R, Alvarez L, Compton AA, Padilla-Parras S. 2017. On the whereabouts of HIV-1 cellular entry and its fusion ports. Trends Mol Med 23:932–913. https://doi.org/10.1016/j.molmed .2017.08.005.
how lentiviruses evolved to replicate in the presence of primate restriction factors. PLoS Pathog 10:e1004017. https://doi.org/10.1371/journal.ppat.1004017.

34. Kozak CA. 2013. Evolution of different antiviral strategies in wild mouse populations exposed to different gammaretroviruses. Curr Opin Virol 3:657–663. https://doi.org/10.1016/j.coviro.2013.08.001.

35. Stoye JP. 2012. Studies of endogenous retroviruses reveal a continuing evolutionary saga. Nat Rev Microbiol 10:395–406. https://doi.org/10.1038/nrmicro2783.

36. Wrensch F, Hoffmann M, Gärtner S, Nehlmeier I, Winkler M, Pöhlsman S. 2017. Virion background and efficiency of virion incorporation determine susceptibility of simian immunodeficiency virus Env-driven viral entry to inhibition by IFITM proteins. J Virol 91:e01488-16. https://doi.org/10.1128/JVI.01488-16.

37. Wolf D, Goff SP. 2008. Host restriction factors blocking retroviral replication. Annu Rev Genet 42:143–163. https://doi.org/10.1146/annurev.genet.42.110807.091704.

38. Buchrieser J, Degrelle SA, Couderc T, Nevers Q, Disson O, Manet C, Donahue PA, Poprot F, Hillion K-H, Pertheau E, Arroyo MV, Souquere S, footage K, Dupressoir A, Heidmann T, Montagutelli X, Fournier T, Lecuit M, Schwartz O. 2019. IFITM proteins inhibit placental syncytiotrophoblast slip formation and promote fetal demise. Science 365:176–180. https://doi.org/10.1126/science.aaw7733.

39. Zani A, Zhang L, McMichael TM, Kenney AD, Chandran K, Hung HC. 2018. IFITM3 directly engages and shuttles into virus-carrying endosomes. J Virol 92:e00196-18. https://doi.org/10.1128/JVI.0196-18.

40. Li S, Ahmed I, Wang Y, Gu C, Zhang L, Zheng Y-H. 2019. Murine leukemia virus glycosylated Gag reduces murine SERINC proteins expression at steady-state levels via the endosome/lysosome pathway to counteract SERINC antiretroviral activity. J Virol 93:35776–35715. https://doi.org/10.1128/JVI.01651-18.

41. Shi J, Xiong R, Zhou T, Su P, Zhang X, Qiu X, Li H, Li S, Yu C, Wang B, Ding C, Smithgall TE, Zheng Y-H. 2018. HIV-1 Nef antagonizes SERINC restrictions by down-regulation of SERINC via the endosome/lysosome system. J Virol 92:e00196-18. https://doi.org/10.1128/JVI.0196-18.

42. Usami Y, Popov S, Göttinger HG. 2014. The Nef-like effect of murine leukemia virus glycosylated Gag on HIV-1 infectivity is mediated by its cytoplasmic domain and depends on the AP-2 adaptor complex. J Virol 88:3443–3454. https://doi.org/10.1128/JVI.01933-13.

43. Shi G, Ozog S, Torbett BE, Compton JA. 2013. mTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3. Proc Natl Acad Sci U S A 110:ES87–96. https://doi.org/10.1073/pnas.1318301113.

44. Xu Z, He Z, Yuan J, Wen W, Huang X, Hu Y, Lin C, Pan J, Li R, Deng H, Liao S, Zhou R, Wu J, Li J, Li M. 2015. IFITM3-containing exosome as a novel mediator for antiviral response in dengue virus infection. Cell Microbiol 17:105–118. https://doi.org/10.1111/cmi.12339.

45. Sharma A, McLaughlin RN, Basom RS, Chandran K, Manet C, Youst JT, Emerman M, Overbaugh J. 2019. Macaque interferon-induced transmembrane proteins inhibit cell fusion mediated by tropheoblast syncytiotrophoblast fusion and promote fetal demise. Science 363:176–180. https://doi.org/10.1126/science.aaw7733.

46. Erwinwe O, Buchholz CJ, Schnierle BS. 2003. The proline-rich region of the retroviral transmembrane protein of murine leukemia virus Glycog, Serinc5, and surface glycoprotein governs virus entry, with opposite effects on gammaretroviral and ebolavirus infection. mBio 7:e01985-16.

47. Reina A, Mirro J, Haynes JG, Ernst SM, Nagashima K. 1994. Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein. J Virol 68:1773–1781.

48. Ragheb JA, Anderson WF. 1994. pH-independent murine leukemia virus ecotropic envelope-mediated cell fusion: implications for the role of the N-terminal domain of the glycoprotein. J Virol 68:3220–3231.

49. Baglio SR, van Eijndhoven MAJ, Koppers-Lalic D, Berenguer J, Lougheed K, Cattaneo PA, Harari M, Arnaud F, Baize S, Dreux M, Gerlier D, Paranhos-Baccala G, Volchkov V, Jiménez JM, Mota V, Perez-Martinez J, Baillie J, Donis RO, Elledge SJ, Brass AL. 2011. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog 7:e1002337. https://doi.org/10.1371/journal.ppat.1002337.

50. Liu S-L, Yount JS. 2019. Interferon-induced transmembrane proteins block fusion of sensitive but not resistant viruses by partitioning into virus-carrying endosomes. PLoS Pathog 15:e1007925. https://doi.org/10.1371/journal.ppat.1007925.

51. Marquardt H, Gilden RV, Oroszlan S. 1977. Envelope glycoproteins of Rauscher murine leukemia virus: isolation and chemical characterization. Biochemistry 16:710–717. https://doi.org/10.1021/bi00623a024.

52. Compton AA, Roy N, Porrot F, Billet A, Casartelli N, Yount JS, Liou C, Lissac A, Schmitz J, van der Heyde J, Darbon JF, Lelievre A, Mangeat P, Sawaya MR, Schwarcz N, Mignot E, Yount JS. 2006. Rein A: mutant murine leukemia virus Gag proteins lacking the membrane-spanning domain. J Virol 68:1773–1781.